GlassScriptPhysician profile
Deepmala Nandanwar
NPI 1942685094
$27,183.59
in general payments reported to CMS, 2019-2025
50 companies · $3,041 in 2025
The $3,041 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $494 · 2021: $619 · 2022: $3,914 · 2023: $3,700 · 2024: $5,394 · 2025: $3,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $72.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,062.91 |
| Education | $72.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $10,060.75 | 2019-2024 | |
| Abbvie INC. | $2,642.60 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $1,303.20 | 2022-2025 | Nuplazid, Daybue |
| Mdd US Operations, LLC | $1,234.46 | 2022-2025 | Gocovri, Gocovri, Apokyn |
| Neurocrine Biosciences, INC. | $1,139.69 | 2021-2025 | Ingrezza |
| Ucb, INC. | $1,135.57 | 2022-2025 | Briviact, Rystiggo, Zilbrysq |
| Ipsen Biopharmaceuticals, INC | $863.20 | 2021-2025 | Dysport |
| Biogen, INC. | $860.44 | 2021-2025 | Vumerity, Avonex, Tysabri |
| Merz Pharmaceuticals, LLC | $805.08 | 2021-2025 | Xeomin, Inbrija |
| Sk Life Science, INC. | $755.53 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $707.54 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $583.13 | 2022-2025 | Rytary, Crexont |
| Medtronic USA, INC. | $494.45 | 2020 | |
| Eisai INC. | $388.68 | 2021-2025 | |
| Kyowa Kirin, INC. | $387.38 | 2021-2025 | Nourianz |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $377.71 | 2022-2024 | Austedo Xr, Austedo |
| Avion Pharmaceuticals | $351.81 | 2022-2023 | Dhivy |
| Pfizer INC. | $323.42 | 2022-2025 | |
| Csl Behring | $288.86 | 2021-2025 | Hizentra |
| Biohaven Pharmaceutical Holding Company LTD. | $265.11 | 2022 | |
| Alexion Pharmaceuticals, INC. | $233.45 | 2019-2025 | Ultomiris |
| Ge Healthcare | $199.11 | 2022-2025 | |
| Lilly USA, LLC | $167.11 | 2023-2025 | Emgality, Amyvid, Kisunla |
| Catalyst Pharmaceuticals, INC. | $151.14 | 2023-2025 | Fycompa |
| Takeda Pharmaceuticals U.S.A., INC. | $146.36 | 2022-2025 | Hyqvia |
| Acorda Therapeutics, INC | $143.87 | 2022-2023 | Inbrija |
| Banner Life Sciences, LLC | $109.00 | 2022-2024 | |
| Amgen INC. | $106.35 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $105.16 | 2023-2024 | Horizant, Horizant |
| Tg Therapeutics, INC. | $94.89 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $84.02 | 2022 | |
| Genzyme Corporation | $71.48 | 2021-2022 | |
| Celgene Corporation | $66.06 | 2022-2025 | Zeposia |
| Arbor Pharmaceuticals, INC. | $64.60 | 2022 | |
| Jazz Pharmaceuticals INC. | $61.06 | 2025 | |
| Revance Therapeutics, INC. | $51.96 | 2024-2025 | Daxxify, Daxi |
| Neurelis, INC. | $50.25 | 2023-2025 | Valtoco |
| Argenx US, INC. | $49.44 | 2023 | Vyvgart, Vyvgart Hytrulo |
| Tanabe Pharma America, INC. | $41.35 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $36.21 | 2021 | |
| Averitas Pharma INC. | $30.00 | 2024 | Qutenza |
| Supernus Pharmaceuticals, INC. | $24.99 | 2023 | |
| Medtronic, INC. | $21.90 | 2025 | Nexframe |
| Emd Serono, INC. | $21.01 | 2022 | |
| Avanir Pharmaceuticals, INC. | $19.34 | 2021 | |
| Adamas Pharmaceuticals, INC. | $16.16 | 2021 | |
| Lundbeck LLC | $13.82 | 2023 | Rexulti |
| Allergan, INC. | $13.13 | 2021 | |
| Abbott Laboratories | $13.12 | 2022 | |
| Aucta Pharmaceuticals, INC. | $8.64 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepmala Nandanwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.